The Math Shows QVML Can Go To $41
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The Invesco S&P 500 QVM Multi-factor ETF (QVML) has an implied analyst target price of $40.78, indicating a potential upside of 17.45% from its current trading price of $34.72. Key holdings with significant upside include GE HealthCare Technologies, Eversource Energy, and C.H. Robinson Worldwide.
Investor Research Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 64.330
Low
80.00
Averages
92.25
High
105.00
Current: 64.330
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into GE HealthCare's Possible Securities Law Violations
- Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
- Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
- Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
See More
GE HealthCare Reports Q1 Earnings Miss, Shares Plunge
- Earnings Report Miss: In Q1 2026, GE HealthCare reported adjusted EPS of $0.99, falling short of the $1.05 consensus estimate, indicating potential profitability challenges that could undermine investor confidence.
- Guidance Downgrade: The company revised its full-year 2026 adjusted EPS guidance down to a range of $4.80 to $5.00 from the previous $4.95 to $5.15, reflecting a cautious outlook on future performance.
- Significant Stock Decline: Following the earnings announcement, GE HealthCare's stock price plummeted from $68.50 to $59.49, a drop of approximately 13%, suggesting heightened market concerns regarding the company's prospects and prompting investors to reassess their positions.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by GE HealthCare and its senior management; while no lawsuits have been filed yet, this inquiry could further impact the company's reputation and stock price.
See More
Latest Wall Street Ratings Overview
- SailPoint Coverage Initiation: Roth initiates coverage of SailPoint with a Buy rating and a price target of $19, highlighting its leadership in Identity Governance and Administration, which is expected to drive future growth potential.
- Brown & Brown Market Outperform: Citizens initiates coverage of Brown & Brown with a Market Outperform rating and a $70 price target, indicating significant upside potential driven by strong market demand and business outlook.
- Ameren Upgrade: JPMorgan upgrades Ameren from Neutral to Overweight, noting that the growing demand from data centers will enhance the company's earnings outlook, with a significant potential increase in EPS CAGR.
- FedEx Rating Reinstatement: Citi reinstates a Buy rating on FedEx with a target price of $443, citing the company's strong performance amid macroeconomic shifts, solid execution, and value unlock from recent spin-offs.
See More
GE HealthCare Faces Investor Lawsuit Investigation
- Earnings Miss: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026, falling short of the $1.05 consensus estimate, which led to a downward revision of its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability.
- Stock Price Plunge: Following the disappointing earnings report, GE HealthCare's stock price dropped by $9.01, or approximately 13%, from $68.50 on April 28, 2026, to $59.49 on April 29, reflecting market concerns about the company's future performance.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether GE HealthCare has violated federal securities laws or engaged in other unlawful business practices, highlighting concerns regarding corporate governance and compliance.
- Investor Rights Advocacy: The law firm is encouraging all investors who purchased GE HealthCare shares during this period and suffered losses to reach out, indicating potential risks and opportunities for compensation related to the company's legal liabilities.
See More
Investigation into GE HealthCare for Possible Securities Law Violations
- Earnings Adjustment: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability that could undermine investor confidence.
- Recall Impact: During the earnings call, management disclosed that profit performance was affected by a recall related to a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Stock Price Plunge: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49, reflecting market concerns about the company's outlook and potentially leading to investor losses.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into GE HealthCare regarding possible violations of federal securities laws, indicating increased legal risks for the company as investors who suffered losses are encouraged to seek legal support.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
Investigation into GE HealthCare's Possible Securities Law Violations
- Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
- Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
- Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
See More
GE HealthCare Reports Q1 Earnings Miss, Shares Plunge
- Earnings Report Miss: In Q1 2026, GE HealthCare reported adjusted EPS of $0.99, falling short of the $1.05 consensus estimate, indicating potential profitability challenges that could undermine investor confidence.
- Guidance Downgrade: The company revised its full-year 2026 adjusted EPS guidance down to a range of $4.80 to $5.00 from the previous $4.95 to $5.15, reflecting a cautious outlook on future performance.
- Significant Stock Decline: Following the earnings announcement, GE HealthCare's stock price plummeted from $68.50 to $59.49, a drop of approximately 13%, suggesting heightened market concerns regarding the company's prospects and prompting investors to reassess their positions.
- Ongoing Legal Investigation: Kirby McInerney LLP is investigating potential violations of federal securities laws by GE HealthCare and its senior management; while no lawsuits have been filed yet, this inquiry could further impact the company's reputation and stock price.
See More
Latest Wall Street Ratings Overview
- SailPoint Coverage Initiation: Roth initiates coverage of SailPoint with a Buy rating and a price target of $19, highlighting its leadership in Identity Governance and Administration, which is expected to drive future growth potential.
- Brown & Brown Market Outperform: Citizens initiates coverage of Brown & Brown with a Market Outperform rating and a $70 price target, indicating significant upside potential driven by strong market demand and business outlook.
- Ameren Upgrade: JPMorgan upgrades Ameren from Neutral to Overweight, noting that the growing demand from data centers will enhance the company's earnings outlook, with a significant potential increase in EPS CAGR.
- FedEx Rating Reinstatement: Citi reinstates a Buy rating on FedEx with a target price of $443, citing the company's strong performance amid macroeconomic shifts, solid execution, and value unlock from recent spin-offs.
See More
GE HealthCare Faces Investor Lawsuit Investigation
- Earnings Miss: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026, falling short of the $1.05 consensus estimate, which led to a downward revision of its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability.
- Stock Price Plunge: Following the disappointing earnings report, GE HealthCare's stock price dropped by $9.01, or approximately 13%, from $68.50 on April 28, 2026, to $59.49 on April 29, reflecting market concerns about the company's future performance.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether GE HealthCare has violated federal securities laws or engaged in other unlawful business practices, highlighting concerns regarding corporate governance and compliance.
- Investor Rights Advocacy: The law firm is encouraging all investors who purchased GE HealthCare shares during this period and suffered losses to reach out, indicating potential risks and opportunities for compensation related to the company's legal liabilities.
See More
Investigation into GE HealthCare for Possible Securities Law Violations
- Earnings Adjustment: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, indicating a significant decline in profitability that could undermine investor confidence.
- Recall Impact: During the earnings call, management disclosed that profit performance was affected by a recall related to a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Stock Price Plunge: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49, reflecting market concerns about the company's outlook and potentially leading to investor losses.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into GE HealthCare regarding possible violations of federal securities laws, indicating increased legal risks for the company as investors who suffered losses are encouraged to seek legal support.
See More
Honeywell's Underperformance Affects Dow Jones Index
- Dow Component Changes: Honeywell replaced Raytheon Technologies in the Dow on August 31, 2020, but has only delivered a 56.2% total return since then, significantly lagging behind RTX's 231.1%, indicating its failure to meet market expectations.
- Unfulfilled Innovation Potential: Although Honeywell was viewed as a diversified and innovative industrial giant in 2020, its persistent underperformance in earnings and free cash flow growth, partly due to supply chain and inflationary pressures, has hindered its ability to capitalize on its strengths.
- Spinoff Plans Generate Interest: In November 2024, activist investor Elliott Investment Management amassed a position exceeding $5 billion, prompting Honeywell to consider a breakup; the successful spinoff of Solstice Advanced Materials in October 2025, which saw a 79.4% gain, highlights the potential for growth through such restructuring.
- Future Outlook and Market Reaction: Honeywell plans to spin off its aerospace division on June 29, 2024, with the remaining business focusing on industrial and building automation, and the market anticipates that this structural adjustment could enhance its standing in the Dow, reflecting a broader preference for focused companies.
See More
